Format

Send to

Choose Destination
Trends Pharmacol Sci. 1997 Nov;18(11):437-44.

CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.

Author information

1
Department of Cancer Research, Merck Research Laboratories, West Point, PA 19486, USA.

Abstract

For Ras oncoproteins to transform mammalian cells, they must be post-translationally farnesylated in a reaction catalysed by the enzyme farnesyl-protein transferase (FPTase). Inhibitors of FPTase have therefore been proposed as anti-cancer agents. In this review Charles Omer and Nancy Kohl discuss the development of FPTase inhibitors that are kinetically competitive with the protein substrate in the farnesylation reaction. These compounds are potent and selective inhibitors of the enzyme that block the tumourigenic phenotypes of ras-transformed cells and human tumour cells in cell culture and in animal models.

PMID:
9426472
DOI:
10.1016/s0165-6147(97)01129-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center